Re: [¹⁷⁷Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study

Affiliations

¹ Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
² Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium. Electronic address: piet.ost@ugent.be.

Comment

Kathia De Man et al. Eur Urol. 2019 Mar.

. 2019 Mar;75(3):536-537.

doi: 10.1016/j.eururo.2018.11.005. Epub 2018 Nov 15.

¹ Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
² Department of Radiation Oncology and Experimental Cancer Research, Ghent University, Ghent, Belgium. Electronic address: piet.ost@ugent.be.

No abstract available

Comment on

[¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.